Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oncopeptides AB

http://www.oncopeptides.se/

Latest From Oncopeptides AB

AZ/Amgen Fail In EU Fast-Track Bid For Tezepelumab

European drug reviewers are not convinced that AstraZeneca and Amgen's investigational treatment for severe asthma, tezepelumab, should be fast-tracked through the EU evaluation system once the companies file for approval.

Review Pathway Respiratory

New EU Filings

Y-mAbs Therapeutics' omburtamab and Oncopeptides' melflufen are among 13 potential new treatments that have been submitted for pan-EU approval.

Europe Review Pathway

Keeping Track: US FDA Acts On 5 Novel Drugs: Approval For Fotivda, Pepaxto, Azstarys; CRLs For Defencath and Oral Paclitaxel

The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker

Approvals Complete Response Letters

AstraZeneca & Amgen Seek EU Fast-Track For Severe Asthma Drug

Tezepelumab was among four products that the European Medicines Agency most recently considered for review under its accelerated assessment mechanism.

Europe Approvals
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
UsernamePublicRestriction

Register